Plantar Fasciitis Treatment Market By Treatment/Product Type (Orthotics, Medication Therapy, Shockwave Therapy, Physical Therapy & Supportive Devices, Surgery and Other Treatments); By Disease/Indication Type (Chronic Plantar Fasciitis, Acute Plantar Fasciitis); By Drug Class (Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Corticosteroids, Other Pharmacological & Injectable Therapies); By End User (Hospitals & Clinics, Home Care/OTC Retail, Ambulatory Surgical Centers [ASCs]); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Plantar Fasciitis Treatment Market: Conservative Care Opens the Door to Advanced Heel Pain Relief

The Global Plantar Fasciitis Treatment Market was valued at USD 1.60 billion in 2025 and is projected to reach USD 2.98 billion by 2032, growing at a CAGR of 9.30% during 2026–2032. Plantar fasciitis is the most common cause of heel pain, generating approximately 1 million patient visits annually in the United States and affecting an estimated 10% of people during their lifetime. Incidence is particularly relevant among adults aged 40–60, runners, and people with overweight or obesity.

 

The treatment pathway is heavily weighted toward conservative care. More than 90–95% of patients improve without surgery through stretching, physical therapy, orthotics, activity modification, and pain management. Only around 3–5% of patients progress to surgery after persistent symptoms despite 6–12 months of conservative treatment.

 

For chronic or treatment-resistant cases, commercial opportunities extend into extracorporeal shock-wave therapy (ESWT), low-level laser therapy, other non-invasive energy devices, injections, and minimally invasive procedures. Companies including Dornier MedTech, STORZ Medical/CuraMedix, and Erchonia participate in device-based treatment categories.

 

Development activity is also exploring regenerative biologics, injectable therapies, and image-guided interventions for persistent heel pain. These approaches could broaden the treatment pathway between conservative management and surgery if supported by successful clinical and regulatory outcomes.

 

The market opportunity therefore depends less on surgical volumes and more on the large recurring patient population seeking non-surgical relief, particularly patients whose symptoms persist despite first-line stretching, orthotics, physical therapy, and medication.

 

Established Treatment Leaders and the Next Wave of Plantar Care

By Treatment / Product Type: Orthotic Support Leads as Shockwave Therapy Expands Clinical Adoption

Leading Subsegment – Orthotics

Orthotics represent the largest category in the Plantar Fasciitis Treatment Market, accounting for an estimated 34.0% share, equivalent to USD 0.544 billion in 2025 revenue, and are projected to expand at a CAGR of 8.65% during 2026–2032. Orthotic inserts help manage plantar fasciitis by supporting the arch, absorbing heel impact, redistributing plantar pressure, and correcting excessive pronation, thereby reducing strain on the plantar fascia. Both prefabricated and custom orthotics are widely used, with custom devices particularly relevant for patients with structural foot abnormalities.

Fastest-Growing Subsegment – Shockwave Therapy

Shockwave Therapy accounts for approximately 17.0% of the Plantar Fasciitis Treatment Market, representing USD 0.272 billion in 2025 revenue, and is projected to be the fastest-growing treatment segment at a 13.25% CAGR during 2026–2032. Extracorporeal shock wave therapy (ESWT) delivers acoustic pulses to the affected plantar fascia to improve blood flow, reduce pain, and stimulate tissue repair. Its growing use in chronic cases that fail conservative treatments, combined with its non-invasive nature, short treatment sessions, and minimal recovery time, supports increasing clinical adoption.

 

By Disease / Indication Type: Chronic Symptoms Shift Spending Toward Advanced Treatment

Leading and Fastest-Growing Subsegment – Chronic Plantar Fasciitis

Chronic Plantar Fasciitis is estimated to lead the Plantar Fasciitis Treatment Market with a 61.0% share, representing USD 0.976 billion in 2025, and is projected to expand at a 10.15% CAGR during 2026–2032. Persistent symptoms lasting six months or longer increasingly require treatment beyond basic inflammation management, as chronic cases involve tissue degeneration, collagen disruption, and impaired healing. This supports greater utilization of extracorporeal shock wave therapy (ESWT), platelet-rich plasma (PRP) injections, advanced physical therapy, and specialized orthotic interventions.

 

By Drug Class: Early Pain Relief Meets Growing Demand for Targeted Injections

Leading Subsegment – NSAIDs

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) account for an estimated 62.0% of the pharmacological treatment segment in the Plantar Fasciitis Treatment Market and are projected to expand at a 7.35% CAGR during 2026–2032. NSAIDs such as ibuprofen and naproxen remain widely used for short-term management of heel pain and acute discomfort, particularly alongside stretching, rest, icing, and orthotics. Their strong accessibility, low cost, and established role in early-stage symptom management continue to support demand, despite limited benefits for chronic degenerative plantar fasciitis.

Fastest-Growing Subsegment – Other Pharmacological & Injectable Therapies

Other pharmacological and injectable therapies, including PRP-based interventions, account for an estimated 11.0% of the pharmacological segment in the Plantar Fasciitis Treatment Market and are projected to record the segment’s fastest 11.65% CAGR during 2026–2032. Demand is shifting toward targeted options for persistent cases that do not respond adequately to stretching, rest, or other conservative care. These therapies include corticosteroid injections, platelet-rich plasma (PRP), botulinum toxin type A, dextrose prolotherapy, autologous blood injections, and oral NSAIDs, supporting pain management and tissue-repair strategies.

 

By End User: Specialist Care and OTC Products Expand Treatment Access

Leading Subsegment – Hospitals & Clinics

Hospitals & Clinics dominate the Plantar Fasciitis Treatment Market with an estimated 57.0% share, representing USD 0.912 billion in 2025 revenue, and are projected to expand at an 8.75% CAGR during 2026–2032. Their leadership reflects comprehensive treatment capabilities spanning clinical diagnosis, imaging, physical therapy, orthotics, and advanced interventions. Patients with persistent symptoms can access corticosteroid or PRP injections, extracorporeal shockwave therapy, and minimally invasive procedures, supporting higher treatment utilization and sustained revenue generation across orthopedic and specialized foot-care departments.

Fastest-Growing Subsegment – Home Care / OTC Retail

Home Care / OTC Retail accounts for approximately 32.0% of the Plantar Fasciitis Treatment Market, equivalent to USD 0.512 billion in 2025 revenue, and is projected to be the fastest-growing end-use segment at a 10.65% CAGR during 2026–2032. Demand is supported by the widespread use of conservative first-line treatments, including OTC arch supports, insoles, heel cups, night splints, athletic tapes, and NSAIDs. Conservative treatment can provide symptom improvement in up to 90% of plantar fasciitis cases, supporting continued retail product adoption.

 

Regional Care Networks Shape the Next Phase of Treatment Growth

Leading Region – North America

North America leads the global plantar fasciitis treatment market, accounting for an estimated 39.0% share, equivalent to USD 0.624 billion in 2025 revenue, and is projected to expand at a CAGR of 8.55% during 2026–2032. Regional demand is supported by a large population affected by obesity, aging-related foot conditions, and prolonged standing or physical activity. Strong healthcare infrastructure and broad access to podiatric care, physical therapy, orthotics, pain management, and minimally invasive treatment options further support treatment adoption across the region.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific is estimated to account for 23.0% of the Plantar Fasciitis Treatment Market, representing approximately USD 0.368 billion in revenue in 2025, and is projected to be the fastest-growing region, expanding at a CAGR of 11.65% during 2026–2032. Growth is supported by expanding orthopedic and podiatric care infrastructure, a rising aging population, and increasing diagnosis of foot and musculoskeletal conditions. Greater adoption of physiotherapy, orthotic devices, corticosteroid injections, shockwave therapy, and minimally invasive treatment options is further strengthening regional treatment demand.

 

Orthotic Scale and Therapy Innovation Shape Competitive Strength

Dr. Scholl’s Connects Foot Scan Data With Consumer Orthotic Design

Dr. Scholl’s Wellness Co. has a particularly strong position in the consumer-facing plantar fasciitis treatment landscape through its broad portfolio of OTC orthotic insoles and heel-pain products. Its Plantar Fasciitis All-Day Pain Relief Orthotics are specifically designed for plantar fasciitis and use arch support, shock absorption, and heel cushioning to reduce pressure on the plantar fascia. Importantly, the company's official product page reports more than 30,000 consumer reviews and approximately 18,000 purchases in a recent month, indicating substantial consumer engagement with this specific plantar fasciitis product. Its newer Advanced Pain Relief Insoles were developed using data from more than 30 million foot scans, illustrating how biomechanical datasets are increasingly being incorporated into mass-market orthotic design.

The company is commercially relevant to the market's orthotics and Home Care/OTC segments, where patients can access treatment without an interventional procedure. This positioning is particularly important because orthotic management is commonly incorporated into conservative plantar fasciitis care before patients progress to higher-intensity interventions.

Enovis Extends Clinical Reach With Targeted Night Splints

Enovis is an important clinical orthopedic-device participant through brands such as ProCare and Aircast, with several products specifically indicated for plantar fasciitis. Its ProCare Plantar Fasciitis Night Splint uses adjustable bilateral dorsiflexion straps and a toe wedge to provide controlled, prolonged stretching of the plantar fascia and Achilles tendon. The company also offers the Pro Night Splint, ProWedge Night Splint, and Aircast Dorsal Night Splint, giving it multiple product configurations across plantar fasciitis supportive care.

This portfolio positions Enovis primarily within the Physical Therapy & Supportive Devices segment and clinical/home rehabilitation channels. Its plantar fasciitis night splint also carries PDAC-assigned L4396/L4397 coding, an important commercial consideration for certain U.S. orthotic-care and reimbursement pathways.

Other Companies and Their Roles in the Plantar Fasciitis Treatment Market

• Superfeet Worldwide: Participates primarily in conservative plantar fasciitis management through supportive insoles designed to improve foot support and reduce stress associated with plantar heel pain.

• Bauerfeind AG: Supplies an extensive foot-orthosis portfolio covering plastic, soft-foam, viscoelastic, and milled insoles; the company reports offering more than 300 types of foot orthoses, strengthening its role in personalized biomechanical support.

• Breg: Competes in supportive treatment with dedicated plantar fasciitis night splints, including adjustable, dorsal, and soft designs intended to maintain controlled plantar-fascia stretching during rest.

• SoftWave Medical: Participates in the non-invasive therapeutic-device space through extracorporeal shockwave/tissue-regeneration technology, making it relevant to the expanding device-based treatment pathway for persistent musculoskeletal pain.

• Ottobock: Contributes through its broader orthopedic and orthotic expertise, particularly customized biomechanical support and clinical orthotic solutions relevant to patients requiring specialist foot management.

• Heel That Pain: Focuses specifically on plantar heel-pain management through heel seats, inserts, and supportive products targeted toward conservative and home-based treatment.

• Orthofeet: Participates through therapeutic footwear and orthotic-support products designed around cushioning, arch support, and pressure management for consumers experiencing foot and heel pain.

• KURU Footwear: Addresses the supportive-footwear segment with heel-cushioning and anatomical support technologies aimed at consumers managing plantar heel discomfort.

• Bioventus: Has relevance to advanced musculoskeletal and regenerative-care pathways, positioning it closer to specialist treatment than conventional OTC plantar fasciitis management.

• Arthrex: Participates primarily at the specialist and procedural end of the market through orthopedic technologies and biologic solutions that can support advanced management of musculoskeletal soft-tissue conditions.

• GSK, Sanofi, and Pfizer: Participate indirectly through OTC analgesic and NSAID portfolios used for short-term pain management; these companies are therefore more relevant to the medication therapy component than to plantar fasciitis-specific device treatment.

 

Analyst Commentary: Precision Orthotics and Regenerative Care Open New Growth Paths

The plantar fasciitis treatment market is shifting from generalized pain management toward targeted, function-preserving care that combines biomechanical correction, regenerative interventions, and non-invasive therapeutic technologies. The strongest growth opportunities are emerging around advanced customized orthotics, data-informed and smart insoles, extracorporeal shockwave therapy, PRP-based regenerative approaches, and minimally invasive treatment pathways for chronic and refractory plantar fasciitis.

 

Plantar Fasciitis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.60 Billion
Revenue Forecast in 2032	USD 2.98 Billion
Overall Growth Rate	CAGR of 9.30% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment / Product Type, By Disease / Indication Type, By Drug Class, By End User, By Geography
By Treatment / Product Type	Orthotics, Medication Therapy, Shockwave Therapy, Physical Therapy & Supportive Devices, Surgery and Other Treatments
By Disease / Indication Type	Chronic Plantar Fasciitis, Acute Plantar Fasciitis
By Drug Class	Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Other Pharmacological & Injectable Therapies
By End User	Hospitals & Clinics, Home Care / OTC Retail, Ambulatory Surgical Centers (ASCs)
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large recurring plantar fasciitis patient population, continued use of conservative treatment, rising demand for orthotics and supportive devices, increasing adoption of extracorporeal shockwave therapy, growing treatment of chronic and refractory cases, expansion of specialist orthopedic and rehabilitation services, and development of regenerative and minimally invasive treatment options
Customization Option	Available upon request